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Abstract The phosphorylation of bovine tau, either by GSK-3 
alone or by a combination of GSK3 and several non-proline- 
dependent protein kinases (non-PDPKs), was studied. GSK3 
alone catalyzed the incorporation of -3 mol 32P/mol tau at a 
relatively slow rate. Prephosphorylation of tau by A-kinase, C- 
kinase, or CK-2 (but not by CK-1, CaM kinase II or Gr kinase) 
increased both the rate and extent of a subsequent phosphoryla- 
tion catalyzed by GSK3 by several-fold. These results suggest 
that the phosphorylation of tau by PDPKs such as GSK3 (and 
possibly MAP kinase, cdk5) may be positively modulated at the 
substrate level by non-PDPK-catalyzed phosphorylations. 
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1. Introduction 
The microtubule-associated protein tau is the main compo- 
nent found in the paired helical filaments (PHF) of Alzheimer 
disease (AD) brain. Compared to tau from normal brain, PHF- 
tau is hyperphosphorylated. Twenty phosphorylation sites have 
been identified in PHF-tau. Eleven of these sites are on Ser/Thr- 
Pro motifs [l]. These sites are probably phosphorylated by 
proline-dependent protein kinases (PDPKs). Members of this 
class include MAP kinase, GSK-3, and cdk5. The identities of 
the kinases responsible for the phosphorylation of the other 
nine sites in PHF-tau are not known. 
Tau has been shown to be a substrate in vitro for several 
protein kinases. Stoichiometric phosphorylation was achieved 
with cyclic AMP-dependent protein kinase (A-kinase) [2,3] cal- 
cium/calmodulin-dependent protein kinase II (CaM kinase II) 
[3,4], protein kinase C [3,5], MAP kinase [6,7], GSK-3 [g-lo], 
cdc2 kinase [ll], cdk5 [12], casein kinase-1 (CK-I), and a cal- 
ciumlcalmodulin-dependent protein kinase from rat cerebellum 
(Gr kinase) [3]. 
The phosphorylation of tau in vivo may involve multiple 
kinases, both PDPKs and non-PDPKs. It is not known how 
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such kinases may interact to bring about the final phosphoryl- 
ation state of tau. One possibility is that the phosphorylation 
state of tau itself may serve as a determinant to dictate substrate 
specificity of different kinases. Such a mode of regulation for 
GSK-3 is well known using other protein substrates. The phos- 
phorylation of glycogen synthase [13], the Rl 1 subunit of A- 
kinase [14], phosphatase inhibitor-2 [15], and protein phosphat- 
ase- 1 G-subunit [ 161 by GSK-3 are enhanced when these pro- 
teins are first phosphorylated by a different kinase. An initial 
phosphorylation of tau by a PDPK (TPKIIlcdkS) was reported 
to stimulate a subsequent phosphorylation catalyzed by TPK 
IIGSK-3 [17]. Alternatively, prior phosphorylation of tau by 
one kinase may serve to inhibit the action of a second kinase. 
In this study we have investigated the interactions among 
PDPKs and non-PDPKs in the phosphorylation of tau. We 
have analyzed how the specificity of GSK-3 (a PDPK) is af- 
fected when the initial phosphorylation state of tau is altered 
by various non-PDPKs. 
2. Experimental 
2.1. Materials 
Bovine brain tau was purified from microtubules obtained by three 
cycles of assembly/disassembly as described [18]. CK-1 and CK-2 [19] 
were purified from bovine brain whereas GSK-3 [20] was from rat 
brain. The GSK-3 preparation contained both the c1 and p isoforms in 
the ratio 3 : 2. CaM kinase II, Gr kinase [21], and C-kinase [22] were 
purified from rat brain. CaM kinase II and Gr kinase were gifts from 
Brad McDonald, Burroughs-Wellcome Laboratories; C-kinase was 
generously supplied by V. Chauhan of this Institute. The catalytic 
subunit of A-kinase and calmodulin were purchased from Sigma Chem- 
ical Co. whereas calf alkaline phosphatase was from Boehringer- 
Mannheim. [y-“P]ATP was purchased from ICN Biomedicals. 
2.2. Methods 
Tau was phosphorylated by GSK-3 in a reaction mixture normally 
containing 0.15 &/ml tau, 6.mM MgCI,, 10 mM 2-mercaptoethanoi, 
0.1 mM Iv-~‘P~ATP. 40 mM HEPES (uH 7.5). and GSK-3. Phosohorvl- 
ation of”tau by the other kinases was recently described by’us fi]. 
Reactions were initiated at 30°C by addition of [Y-‘~P]ATP and, after 
the desired incubation time, stopped by addition of SDS-stop solution 
and processed as described [3]. GSK-3 activity was measured using 
myelin basic protein as a substrate. One unit of GSK-3 activity is 
defined as the imount of the kinase that will catalyze the incorporation 
of 1 nmol “P/min into myelin basic protein (1 mg/ml) at 30°C. 
Tau was dephosphorylated with calf intestine alkaline phosphatase 
as previously described [17]. 
3. Results 
3.1. Phosphorylation of tau by GSK-3 
It was previously shown that maximal phosphorylation of 
tau by GSK-3 requires up to 20 h incubation at 37°C [S]. Since 
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Fig. I. Time course of phosphorylation of tau by GSK-3. Tau was 
phosphorylated by GSK-3, aliquots of the phosphorylation mixture 
were removed at different times and the reaction stopped by addition 
of SDS-stop solution. ‘2P-labelled tau was resolved from other proteins 
by SDS-PAGE, excised from the gels and “P incorporation determined 
by Cerenkov counting. 
phosphorylation events occur relatively rapidly in cells, we have 
further examined tau phosphorylation by GSK-3. We first op- 
timized the reaction conditions. We established that maximal 
“P incorporation into tau by GSK-3 occurred at 3-5 mM 
MgCl, and at 0.1 mM ATP at pH 7.5. MnCl, could not substi- 
tute for MgClz in reaction mixtures: in the presence of 3 mM 
MnCl,, GSK-3 activity was less than 2% of that found with 
3 mM Mg2+ (data not shown). Under these optima1 conditions 
GSK-3 catalyzed the incorporation of -3 mol “P into tau in 
4 h/30”C (Fig. 1). The first - 1.5 mol 32P is incorporated in 1 h, 
additional phosphorylation occurring only slowly (- 1.5 mol 
“PI3 h). 
3.2. Phosphorylation of tau by a combination of GSK-3 and other 
kinases 
One possible reason to explain the slow rate at which tau is 
phosphorylated by GSK-3 (Fig. 1 and [S]) is that the phospho- 
rylation of other sites on tau by a second kinase may be re- 
quired. Such modulation of GSK-3 activity at the level of the 
protein substrate has previously been shown [ 13-161. We there- 
fore separately phosphorylated tau with six different kinases 
(CK-I, CK-2, A-kinase, C-kinase, CaM kinase II, Gr kinase) 
and used these different phosphorylated tau species as sub- 
strates for GSK-3 (Figs. 2 and 3). The phosphorylation of tau 
by the above six kinases has been studied in detail elsewhere 
[3], and will be dealt with here only briefly. After 60 min, 32P 
incorporation catalyzed into tau by A-kinase, C-kinase, CK-2, 
CK-1, CaM kinase II, and Gr kinase was approximately 2.0 
mol, 1.6 mol, 0.6 mol, 3.5 mol, 3.0 mol, and 1.4 mol, respectively 
(Figs. 2 and 3). When these different phosphorylated species of 
tau were used as substrates for GSK-3, the latter kinase further 
phosphorylated tau. After 60 min incubation, the net 32P incor- 
poration catalyzed by GSK-3 was 2.8 mol, 3.3 mol, 4.2 mol, 1.1 
mol, 1 .O mol, and 2.2 mol for tau that was prephosphorylated 
with A-kinase. C-kinase, CK-2, CK-1, CaM kinase II, and Gr 
kinase, respectively. 
From the results of Figs. 2 and 3 it is clear that GSK-3 in 
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combination with another kinase catalyzed a higher “P incor- 
poration into tau than achieved by that kinase alone. From the 
data of Figs. 2 and 3, the net “P incorporation into tau cata- 
lyzed by GSK-3 alone was calculated. This was then compared 
with “P incorporation achieved by GSK-3 using tau that was 
not prephosphorylated. The results are shown in Fig. 4. It can 
be seen that when tau was prephosphorylated by A-kinase, 
C-kinase, and CK-2, both the rate and extent of ‘*P incorpora- 
tion was increased compared to tau that was not pre- 
phosphorylated. The rate of j2P incorporation was increased 
3.4-, 2.5-, and 2.4-fold and its extent (after 60 min) 1.9-, 2.3-, 
and 2.9-fold, respectively (Fig. 4A). After prephosphorylation 
of tau by CK-1 or CaM kinase 11. both the rate and extent of 
! 
0 20 40 60 80 100 120 
Time (min) 
Fig. 2. Phosphorylation of tau by a combination of A-kinase, C-kinase, 
CK-2, and GSK-3. Tau was separately phosphorylated by A-kinase 
(&A), C-kinase (o,B), and CK-2 (o,(Z), and aliquots removed at differ- 
ent times for determination of “P incorporation. After 60 min (J), 
aliquots of the reaction mixtures were separately removed and supple- 
mented with GSK-3 (A,=,.). The incubations were continued and aliquots 
removed at different times to determine “P incorporation into tau. 
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Fig. 3. Phosphorylation of tau by a combination of CK-1, CaM kinase 
II, Gr kinase, and GSK-3. Tau was separately phosphorylated by CK-1 
(a,A), CaM kinase II (o,B) and Gr kinase (o,C). After 60 min (J), 
aliquots of the reaction mixtures were separately removed and supple- 
mented with GSK-3 (A,&.) and the incubations continued. 
‘*P incorporation by GSK-3 was decreased. Although the rate 
is also decreased after prephosphorylation with Gr kinase, the 
extent of ‘*P incorporation is slightly elevated (1.5fold) (Fig. 
4B). These results suggest that GSK-3-catalyzed phosphoryla- 
tion of tau may be positively modulated by A-kinase, C-kinase, 
and CK-2 but not by CK-1, CaM kinase II or Gr kinase. 
3.3. Role oj’endogenous tau phosphorylation 
It was previously shown that purified bovine tau is already 
phosphorylated at Ser-144 and Ser-315. Treatment of such tau 
with calf alkaline phosphatase can completely remove the phos- 
phates from these sites [17]. We investigated what role, if any, 
these endogenous phosphates play in modulating the specificity 
of the seven kinases for different phosphorylation sites on tau. 
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For these studies tau was dephosphorylated with calf alkaline 
phosphatase as described [ 171. The rate and extent of phospho- 
rylation of the dephospho-tau and non-dephospho-tau by 
GSK-3 and the six other kinases were then compared. A typical 
result is shown in Fig. 5. It can be seen that the same rate and 
extent of ‘*P incorporation is catalyzed by A-kinase whether 
tau was initially dephosphorylated (Fig. 5B) or not (Fig. 5A). 
Similarly, no differences in the phosphorylation of these two 
species of tau was observed using C-kinase, CK-2, CK- 1, CaM 
kinase II, Gr kinase, or GSK-3 (data not shown). Further, a 
repeat of the experiments outlined in Fig. 2 using 
dephosphorylated tau and a combination of GSK-3 and A- 
kinase, C-kinase, or CK-2, did not change the previous results. 
Fig. 5 also shows such an experiment using a combination of 
A-kinase and GSK-3. These results suggest that phosphoryla- 
tion of Ser- 144 and Ser-3 15 do not play a major role in modu- 
lating the specificity of GSK-3 for different sites on tau. 
4. Discussion 
In an earlier study [3] we have shown that tau can be stoi- 
chiometrically phosphorylated by five non-PDPKs: A-kinase, 
C-kinase, CK-1, CaM kinase II, and Gr kinase. Substoichiom- 
etric phosphorylation was obtained with a sixth non-PDPK- 
CK-2. CK-1 and CaM kinase II catalyzed the highest levels of 
“P incorporation into tau. When these two kinases were used 
in combination, an even higher level of ‘*P incorporation into 
tau was achieved [3]. 
In the present study, the phosphorylation of tau by GSK-3 
was studied. This kinase catalyzed the incorporation of -2 mol 
‘*P/m01 tau in 2 h. Additional phosphorylation of tau occurred 
only slowly. It has been established previously that the rate and 
extent of GSK-3-catalyzed phosphorylation can be modulated 
by a prior phosphorylation of the particular protein substrate 
[13-161. Hence, we have explored the potential interaction be- 
tween GSK-3 and six non-PDPKs (A-kinase, C-kinase, CK-1, 
CK-2, CaM kinase II, Gr kinase). We reasoned that pre- 
phosphorylation of tau by one or more of these kinases may 
make tau a better substrate for GSK-3. Our results indicate that 
prephosphorylation of tau by three of the kinases (A-kinase, 
C-kinase, CK-2) increased both the rate and level of ‘*P incor- 
poration catalyzed by GSK-3 several-fold. Although both A- 
kinase and CK-2 have been shown to modulate GSK-3 activity 
by prephosphorylation of other protein substrates [13-161, this 
is the first report of such modulation by C-kinase. After pre- 
phosphorylation by CK-2, for example, GSK-3 catalyzed an 
incorporation of greater than 4 mol ‘*P/60 min. By comparison, 
a 20 h incubation with GSK-3 (no prephosphorylation of tau) 
was required to achieve this level of phosphorylation [S]. In a 
separate study [9], 4 mol 32Plmol tau were incorporated after 
3 h incubation with GSK-3. Even though the time is shorter 
compared to the previous study (3 h vs. 20 h), it is still inferior 
compared to that observed when tau is prephosphorylated with 
CK-2 (1 h vs. 3 h). In addition, the concentration of GSK-3 (25 
pug/ml) used in the latter study [9] was relatively high. This can 
be compared to 2 ,@ml GSK-3 used in our study. Unlike 
A-kinase, C-kinase, and CK-2, prephosphorylation of tau by 
CK-1, CaM kinase II or Gr kinase did not enhance the subse- 
quent GSK-3-catalyzed phosphorylation. On the contrary, 
GSK-3-catalyzed ‘*P incorporation decreased after pre- 
phosphorylation of tau by CK-1 and CaM kinase II. These 
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Fig. 4. Comparison of the GSK-3-catalyzed phosphorylations of tau which was prephosphorylated by various non-PDPKs. Tau was separately 
prephosphorylated for 60 min by CK-2 (n), C-kinase (0). A-kinase (o), Gr kinase (o), CK-1 (v). and CaM kinase 11 (m) and then used as a substrate 
for GSK-3. The net “P incorporation catalyzed by GSK-3 alone is shown. For comparison, GSK-3 catalyzed phosphorylation of tau that was not 
prephosphorylated by any kinase (0) is shown 
results suggest that after an initial phosphorylation of tau by 
the latter two kinases, it assumes conformations that are unfa- 
vorable for subsequent GSK-3-catalyzed phosphorylations. 
We have also evaluated how the specificities of the different 
kinases are affected by endogenous phosphorylation of tau. It 
was previously shown that Ser-144 and Ser-315 are already in 
a phosphorylated state in purified bovine tau. These phos- 
phates could be removed by alkaline phosphatase [17]. We have 
compared the rates of phosphorylation of dephospho-tau and 
non-dephospho-tau by GSK-3, A-kinase, C-kinase, and CK-2, 
either singly or in combination. Our results suggest that the 
phosphorylation states of Ser-144 and/or Ser-315 do not mod- 
ulate the site specificities of GSK-3 or the other kinases. CK-2 
and C-kinase have been shown to phosphorylated Thr-39 [23] 
and Ser-324 (equivalent to Ser-313 in bovine tau) [5], respec- 
tively, in human tau 40 (441 amino acids). A-kinase also 
phosphorylated Ser-324, in addition to Ser-214, Ser-356, Ser- 
409, and Ser-416 1241. From our results it can be inferred that 
prephosphorylation of Thr-39 and Ser-324 changes tau confor- 
mation in such a way that additional sites not normally acces- 
sible to GSK-3 can now be readily phosphorylated by this 
kinase. Previous studies have shown that GSK-3 can phospho- 
rylate Ser- 199, Thr-23 1, Ser-235, Ser-396, Ser-404, and Ser-413 
in human tau 40 [9,25]. It is still to be clarified whether the 
higher levels of phosphorylation of tau by GSK-3 (see Fig. 2) 
lead to increased inhibition of tau-stimulated microtubule as- 
sembly. Phosphorylation of tau by either A-kinase or C-kinase 
was shown to inhibit such assembly [24.26]. 
Our results help to emphasize the importance of the phos- 
phorylation state of tau in dictating kinase specificity. Since 
PHF-tau is phosphorylated at both pro- and non-pro-directed 
sites [l], both PDPKs and non-PDPKs may participate in 
bringing about its hyperphosphorylated state. In this study we 
have demonstrated that the specificity of a PDPK (GSK-3) can 
be modulated by several non-PDPKs. A similar type of modu- 
lation of the specificities of other PDPKs (MAP kinase, cdk5) 
160 0 40 80 120 160 200 
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Fig. 5. Comparison of the phosphorylations of dephosphorylated tau with tau not previously dephosphorylated. Tau that was either dephosphorylated 
(B) with alkaline phosphatase or was not dephosphorylated (A) was used as a substrate for A-kinase (A.0). After 60 min (J), aliquots of the reaction 
mixtures were separately removed and supplemented with GSK-3 (A,.) as described for Fig. 2. 
8 
by the same or other non-PDPKs is also possible. Other types 
of modulation such as PDPK-PDPK and non-PDPK-non- 
PDPK are also possible in tau phosphorylation. It has been 
reported that a prior phosphorylation of tau by TPK IIlcdkS 
(a PDPK) can modulate the site specificity of TPK IIGKS-3 
(another PDPK) [17]. 
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